Dr. Daniel Y. Wang, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 91
Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TX license R7348 (first issued 2018; active) -
Internal Medicine Physician
TX license BP10043123 -
Medical Oncology Physician
TX license R7348 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- University of Texas Southwestern Medical Center at Dallas (3,187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 91
- Services billed
- 330
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 140 | 43 |
| Established patient office or other outpatient visit, 30-39 minutes | 38 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 27 | 27 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Houston, TX | 24 |
| Levothyroxine Sodium Other prescribers in Houston, TX | 22 |
| Prochlorperazine Maleate Other prescribers in Houston, TX | 21 |
| Ondansetron Hcl Other prescribers in Houston, TX | 19 |
| Eliquis (apixaban) Other prescribers in Houston, TX | 16 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Houston, TX | 16 |
| Hydroxyzine Hcl Other prescribers in Houston, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $2,017 in total to this clinician.
| Springworks Therapeutics, Inc. | $2,000 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $17.20 |
| Consulting Fee | $2,000 |
|---|---|
| Food and Beverage | $17.20 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Springworks Therapeutics, Inc. Mar 13, 2025 | Consulting Fee OGSIVEO · DESMOID TUMORS | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $786,687 in research payments for these studies, mostly to the institutions running them.
- A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05608291 - Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT03969004 - A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK 4280A, a Coformulation of Favezelimab MK-4280 with Pembrolizumab MK-3475 in Selected Solid Tumors KeyForm-010
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.